Eli Lilly (LLY) announced that the US Food and Drug Administration (or FDA) approved the Humalog Junior KwikPen for finer dose adjustments in the treatment of patients with diabetes on June 13, 2017.
Tanezumab is an investigational drug co-developed by Eli Lilly (LLY) and Pfizer (PFE).
On June 15, 2017, Eli Lilly announced data from a study that evaluated the safety and efficacy of Taltz in patients with active psoriatic arthritis.
On June 14, 2017, in a Reuters survey including 25 brokerage companies, 56% of the analysts gave Medtronic a “buy” rating, while 44% rated it as a “hold.”
In January 2017, Medtronic received FDA IDE approval to initiate a study of its IN.PACT AV Access DCB for a new indication in ESRD patients.
On June 6, 2017, Medtronic (MDT) received the Health Canada license for its SureTune3 software for DBS (deep brain stimulation) therapy.
Incyte (INCY) distributes its key drug Jakafi through its own network of specialty pharmacy providers and wholesalers in the US.
Incyte’s (INCY) product portfolio includes oncology and non-oncology drugs.
Incyte’s (INCY) Jakafi (ruxolitinib) is the only FDA-approved drug for the treatment of myelofibrosis and polycythemia vera, both of which are rare types of blood cancer.
Incyte (INCY) reported revenues of $384.1 million in its 1Q17 results, which translates to 45.7% revenue growth in 1Q17 as compared to $263.5 million in 1Q16.
Incyte’s (INCY) consolidated revenues rose ~45.7% to $384.1 million in 1Q17 as compared to $263.5 million in 1Q16.
Incyte reported revenues of $384.1 million in 1Q17 as compared to $263.5 million in 1Q16.
On April 18, Medtronic announced the divestiture of its Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses to Cardinal Health.
AbbVie (ABBV) has a focused immunology pipeline in order to address various dermatologic and gastrointestinal conditions.
Of the 21 analysts covering AbbVie in June 2017, three have recommended “strong buys,” while six have recommended “buys.”
In 2016, AbbVie (ABBV) reported net revenue of ~$25.6 billion, which reflected a rise of ~12% year-over-year (or YoY).
In 2016, AbbVie’s (ABBV) Duodopa, a combination drug for the treatment of advanced Parkinson’s disease, generated revenue of ~$293 million.
In 2016, AbbVie’s (ABBV) Lupron generated revenue of $821 million, a slight fall of 0.6% year-over-year (or YoY). In 1Q17, Lupron reported revenue of ~$194 million.
In November 2013, AbbVie’s (ABBV) Imbruvica received approval from the FDA for the treatment of mantle cell lymphoma (or MCL).
In 2016, AbbVie’s (ABBV) Viekira generated revenue of ~$1.5 billion, a fall of ~7% year-over-year (or YoY). In 1Q17, the drug reported revenue of ~$236 million.